Celldex Therapeutics (CLDX) Other Working Capital Changes (2010 - 2026)

Celldex Therapeutics' Other Working Capital Changes history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 213.6% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $5.0 million (up 22.77% YoY), while the FY2025 annual figure was $3.6 million, down 62.54% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $2.1 million, down from $4.0 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $7.1 million in Q1 2022, with the low at -$4.1 million in Q4 2023.
• The 5-year median for Other Working Capital Changes is $999500.0 (2022), against an average of $1.2 million.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes surged 521.54% in 2022, then slumped 352.01% in 2023.
• Celldex Therapeutics' Other Working Capital Changes stood at $1.6 million in 2022, then tumbled by 352.01% to -$4.1 million in 2023, then soared by 197.27% to $4.0 million in 2024, then dropped by 0.89% to $4.0 million in 2025, then plunged by 48.02% to $2.1 million in 2026.
• Business Quant data shows CLDX's Other Working Capital Changes at $2.1 million in Q1 2026, $4.0 million in Q4 2025, and $64000.0 in Q3 2025.